Bernstein Initiates Coverage On Jazz Pharmaceuticals with Market Perform Rating, Announces Price Target of $229
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Bernstein analyst Jeffrey Walch initiates coverage on Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Market Perform rating and announces Price Target of $229.